GLP-1 RAs and SGLT2i are cornerstone cardiometabolic therapies with complementary metabolic, vascular, and anti-inflammatory effects for secondary prevention in ASCVD [13,14]. This evidence concerns the gene GLP1R and atherosclerosis.